Komori
Earnings7775DAIKEN MEDICAL CO.,LTD.Electrical Equipment and Precision Instruments

Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated)

Revenue for the first half increased slightly, up 0.8% year on year, while operating profit fell 29.3% and net income fell 28.0%. Higher material and labor costs weighed on profit, but the full-year forecasts for earnings and dividends were left unchanged.

Worth reading
43Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
29.3
% (year-on-year decline in operating income)
Wording
Conditional
How definitive the wording is.

Results for this period

Interim period (second quarter)1 April 2026 to 30 September 2026Non-consolidated (standalone)Japanese GAAP
Net Sales5,097¥ millionYear on year +0.8%Progress 48.5%
Operating profit478¥ millionYear on year -29.3%Progress 56.9%
Ordinary income474¥ millionYear on year -29.7%Progress 57.5%
Net income attributable to owners of the parent368¥ millionYear on year -28.0%Progress 62.4%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥12.84
Financial position at period-end
Total assets10,915¥ million
of which net assets 7,829 ¥ millionEquity ratio 71.5%vs. prior year-end +3.3pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating+58
Investment-261
Financials-554
Net change-757

Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period¥2,020 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥10,500 million (YoY +2.0%)
Operating profit¥840 million (YoY -34.3%)
Ordinary income¥825 million (YoY -35.3%)
Net income¥590 million (YoY -36.1%)
Annual Dividend Forecast¥20 → ¥20(0.0%)
Factors Behind Changes in Business Performance

Revenue increased mainly because sales of FitFix and COOPDECH Aimy PCA remained strong. Operating profit decreased due to a decline in gross profit resulting from higher material costs, as well as an increase in selling, general and administrative expenses resulting from higher labor costs.

Disclosure regarding the going concern assumption

No applicable matters.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Breakdown of extraordinary income (loss)Gain on reversal of subscription rights to shares 809 Thousands of yen, Loss on retirement of non-current assets 6,441 Thousands of yen
Depreciation and amortization¥143 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNo
Issued Shares at Period-End31,840,000
Treasury Shares at Period-End3,111,563
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedNon-consolidated (standalone)
Period Covered1 April 2026 to 30 September 2026
Net Sales¥5,097 million (YoY +0.8%)
Operating profit¥478 million (YoY -29.3%)
Ordinary income¥474 million (YoY -29.7%)
Profit attributable to owners of the parent¥368 million (YoY -28.0%)
Net income per share¥12.84
Equity ratioEnd of the current fiscal period 71.5 / End of previous period 68.2
Total assets¥10,915 million
Net assets¥7,829 million
Cash flows from operating activities¥58 million
Cash flows from investing activities¥-261 million
Cash flows from financing activities¥-554 million
Cash and cash equivalents at end of period¥2,020 million
Full-year earnings forecastNet Sales ¥10,500 million (YoY +2.0%) / Operating profit ¥840 million (YoY -34.3%) / Ordinary income ¥825 million (YoY -35.3%) / Net income ¥590 million (YoY -36.1%)
Annual Dividend Forecast¥20 → ¥20(0.0%)
Depreciation and amortization¥143 million
Breakdown of extraordinary income (loss)Gain on reversal of subscription rights to shares 809 Thousands of yen, Loss on retirement of non-current assets 6,441 Thousands of yen
Disclosure regarding the going concern assumptionNo applicable matters.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNo
Issued Shares at Period-End31,840,000
Treasury Shares at Period-End3,111,563
Factors Behind Changes in Business PerformanceRevenue increased mainly because sales of FitFix and COOPDECH Aimy PCA remained strong. Operating profit decreased due to a decline in gross profit resulting from higher material costs, as well as an increase in selling, general and administrative expenses resulting from higher labor costs.
Items this document does not state (11)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossChanges in the scope of consolidationMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue increased mainly because sales of FitFix and COOPDECH Aimy PCA remained strong. Operating profit decreased due to a decline in gross profit resulting from higher material costs, as well as an increase in selling, general and administrative expenses resulting from higher labor costs.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated) | DAIKEN MEDICAL CO.,LTD. (7775) timely disclosure | Komori